Dr Leeza Osipenko and colleagues analysed the quality of clinical evidence submitted by companies to NICE technology appraisals (TAs) over the last 20 years.
The way HTAs are conducted in Europe is changing. And, if organisations act now to overcome the challenges, they could reap the rewards for years to come.
It’s been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats.
Creating healthcare interventions and technological solutions that work is hard enough. But when the goal is sustainable system-wide improvement, it’s the easy part.
The passage of the Inflation Reduction Act (IRA) signifies more than just a legislative milestone; it acts as a clarion call to the pharmaceutical industry.
Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall
The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin